Home Nanotechnology Inhalable extracellular vesicle supply of IL-12 mRNA to deal with lung most cancers and promote systemic immunity

Inhalable extracellular vesicle supply of IL-12 mRNA to deal with lung most cancers and promote systemic immunity

0
Inhalable extracellular vesicle supply of IL-12 mRNA to deal with lung most cancers and promote systemic immunity

[ad_1]

  • Wolchok, J. D. et al. General survival with mixed nivolumab and ipilimumab in superior melanoma. N. Engl. J. Med. 377, 1345–1356 (2017).

    Article 
    CAS 

    Google Scholar
     

  • Ito, A., Kondo, S., Tada, Okay. & Kitano, S. Medical improvement of immune checkpoint inhibitors. BioMed. Res. Int. 2015, 605478 (2015).

    Article 

    Google Scholar
     

  • Anderson, Okay. G., Stromnes, I. M. & Greenberg, P. D. Obstacles posed by the tumor microenvironment to T cell exercise: a case for synergistic therapies. Most cancers Cell 31, 311–325 (2017).

    Article 
    CAS 

    Google Scholar
     

  • Shi, Y. et al. Subsequent-generation immunotherapies to enhance anticancer immunity. Entrance. Pharmacol. 11, 566401 (2020).

    Article 
    CAS 

    Google Scholar
     

  • Mirlekar, B. & Pylayeva-Gupta, Y. IL-12 household cytokines in most cancers and immunotherapy. Cancers (Basel). 13, 167 (2021).

    Article 
    CAS 

    Google Scholar
     

  • Del Vecchio, M. et al. Interleukin-12: organic properties and scientific utility. Clin. Most cancers Res. 13, 4677–4685 (2007).

    Article 

    Google Scholar
     

  • Trinchieri, G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat. Rev. Immunol. 3, 133–146 (2003).

    Article 
    CAS 

    Google Scholar
     

  • Nguyen, Okay. G. et al. Localized interleukin-12 for most cancers immunotherapy. Entrance Immunol. 11, 575597 (2020).

    Article 
    CAS 

    Google Scholar
     

  • Moynihan, Okay. D. et al. Eradication of enormous established tumors in mice by mixture immunotherapy that engages innate and adaptive immune responses. Nat. Med. 22, 1402–1410 (2016).

    Article 
    CAS 

    Google Scholar
     

  • Mace, T. A. et al. IL-6 and PD-L1 antibody blockade mixture remedy reduces tumour development in murine fashions of pancreatic most cancers. Intestine 67, 320–332 (2018).

    Article 
    CAS 

    Google Scholar
     

  • Agarwal, Y. et al. Intratumourally injected alum-tethered cytokines elicit potent and safer native and systemic anticancer immunity. Nat. Biomed. Eng. 6, 129–143 (2022).

    Article 
    CAS 

    Google Scholar
     

  • Jorgovanovic, D., Track, M., Wang, L. & Zhang, Y. Roles of IFN-γ in tumor development and regression: a evaluate. Biomark. Res. 8, 49 (2020).

    Article 

    Google Scholar
     

  • Hotz, C. et al. Native supply of mRNA-encoded cytokines promotes antitumor immunity and tumor eradication throughout a number of preclinical tumor fashions. Sci. Transl. Med. 13, eabc7804 (2021).

    Article 
    CAS 

    Google Scholar
     

  • Li, Y. et al. Multifunctional oncolytic nanoparticles ship self-replicating IL-12 RNA to remove established tumors and prime systemic immunity. Nat. Most cancers 1, 882–893 (2020).

    Article 
    CAS 

    Google Scholar
     

  • Liu, J. Q. et al. Intratumoral supply of IL-12 and IL-27 mRNA utilizing lipid nanoparticles for most cancers immunotherapy. J. Management. Launch 345, 306–313 (2022).

    Article 
    CAS 

    Google Scholar
     

  • Liu, M. A. A comparability of plasmid DNA and mRNA as vaccine applied sciences. Vaccines 7, 37 (2019).

    Article 
    CAS 

    Google Scholar
     

  • Sangro, B. et al. Section I trial of intratumoral injection of an adenovirus encoding interleukin-12 for superior digestive tumors. J. Clin. Oncol. 22, 1389–1397 (2004).

    Article 
    CAS 

    Google Scholar
     

  • Qiu, N. et al. Tumor-associated macrophage and tumor-cell dually transfecting polyplexes for environment friendly interleukin-12 most cancers gene remedy. Adv. Mater. 33, e2006189 (2021).

    Article 

    Google Scholar
     

  • Hewitt, S. L. et al. Intratumoral IL12 mRNA remedy promotes TH1 transformation of the tumor microenvironment. Clin. Most cancers Res. 26, 6284–6298 (2020).

    Article 
    CAS 

    Google Scholar
     

  • Aslan, C. et al. Exosomes for mRNA supply: a novel biotherapeutic technique with hurdles and hope. BMC Biotechnol. 21, 20 (2021).

    Article 
    CAS 

    Google Scholar
     

  • Popowski, Okay. D. et al. Inhalable dry powder mRNA vaccines based mostly on extracellular vesicles. Matter 5, 2960–2974 (2022).

    Article 
    CAS 

    Google Scholar
     

  • O’Brien, Okay., Breyne, Okay., Ughetto, S., Laurent, L. C. & Breakefield, X. O. RNA supply by extracellular vesicles in mammalian cells and its purposes. Nat. Rev. Mol. Cell Biol. 21, 585–606 (2020).

    Article 

    Google Scholar
     

  • Zickler, A. M. & El Andaloussi, S. Purposeful extracellular vesicles aplenty. Nat. Biomed. Eng. 4, 9–11 (2020).

    Article 

    Google Scholar
     

  • Cheng, Okay. & Kalluri, R. Pointers for scientific translation and commercialization of extracellular vesicles and exosomes based mostly therapeutics. Extracell. Vesicle 2, 100029 (2023).

    Article 

    Google Scholar
     

  • Dinh, P. C. et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung restore in pulmonary fibrosis. Nat. Commun. 11, 1064 (2020).

    Article 
    CAS 

    Google Scholar
     

  • Wang, Z. et al. Exosomes embellished with a recombinant SARS-CoV-2 receptor-binding area as an inhalable COVID-19 vaccine. Nat. Biomed. Eng. 6, 791–805 (2022).

    Article 
    CAS 

    Google Scholar
     

  • Li, Z. et al. Cell-mimicking nanodecoys neutralize SARS-CoV-2 and mitigate lung harm in a non-human primate mannequin of COVID-19. Nat. Nanotechnol. 16, 942–951 (2021).

    Article 
    CAS 

    Google Scholar
     

  • Douguet, L. et al. A small-molecule P2RX7 activator promotes anti-tumor immune responses and sensitizes lung tumor to immunotherapy. Nat. Commun. 12, 653 (2021).

    Article 
    CAS 

    Google Scholar
     

  • Casanova-Acebes, M. et al. Tissue-resident macrophages present a pro-tumorigenic area of interest to early NSCLC cells. Nature 595, 578–584 (2021).

    Article 
    CAS 

    Google Scholar
     

  • Zhu, X. et al. Complete toxicity and immunogenicity research reveal minimal results in mice following sustained dosing of extracellular vesicles derived from HEK293T cells. J. Extracell. Vesicles 6, 1324730 (2017).

    Article 

    Google Scholar
     

  • Mizrak, A. et al. Genetically engineered microvesicles carrying suicide mRNA/protein inhibit schwannoma tumor progress. Mol. Ther. 21, 101–108 (2013).

    Article 
    CAS 

    Google Scholar
     

  • Kojima, R. et al. Designer exosomes produced by implanted cells intracerebrally ship therapeutic cargo for Parkinson’s illness therapy. Nat. Commun. 9, 1305 (2018).

    Article 

    Google Scholar
     

  • Usman, W. M. et al. Environment friendly RNA drug supply utilizing crimson blood cell extracellular vesicles. Nat. Commun. 9, 2359 (2018).

    Article 

    Google Scholar
     

  • Lieschke, G. J., Rao, P. Okay., Gately, M. Okay. & Mulligan, R. C. Bioactive murine and human interleukin-12 fusion proteins which retain antitumor exercise in vivo. Nat. Biotechnol. 15, 35–40 (1997).

    Article 
    CAS 

    Google Scholar
     

  • Tsai, S. J. et al. Exosome-mediated mRNA supply in vivo is protected and can be utilized to induce SARS-CoV-2 immunity. J. Biol. Chem. 297, 101266 (2021).

    Article 
    CAS 

    Google Scholar
     

  • Li, B. et al. Combinatorial design of nanoparticles for pulmonary mRNA supply and genome modifying. Nat. Biotechnol. 41, 1410–1415 (2023).

    Article 
    CAS 

    Google Scholar
     

  • Gao, S., Wang, L., Liu, W., Wu, Y. & Yuan, Z. The synergistic impact of homocysteine and lipopolysaccharide on the differentiation and conversion of raw264.7 macrophages. J. Inflamm. 11, 13 (2014).

    Article 

    Google Scholar
     

  • Mei, X. et al. An inhaled bioadhesive hydrogel to protect non-human primates from SARS-CoV-2 an infection. Nat. Mater. 22, 903–912 (2023).

    Article 
    CAS 

    Google Scholar
     

  • Olivo Pimentel, V. et al. Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when mixed with radiotherapy. J. Immunother. Most cancers 9, e001764 (2021).

    Article 

    Google Scholar
     

  • Leonard, J. P. et al. Results of single-dose interleukin-12 publicity on interleukin-12-associated toxicity and interferon-gamma manufacturing. Blood 90, 2541–2548 (1997).

    CAS 

    Google Scholar
     

  • Chiocca, E. A. et al. Regulatable interleukin-12 gene remedy in sufferers with recurrent high-grade glioma: outcomes of a part 1 trial. Sci. Transl. Med. 11, eaaw5680 (2019).

    Article 

    Google Scholar
     

  • Liu, Y. et al. Armored inducible expression of IL-12 enhances antitumor exercise of glypican-3-targeted chimeric antigen receptor-engineered T cells in hepatocellular carcinoma. J. Immunol. 203, 198–207 (2019).

    Article 
    CAS 

    Google Scholar
     

  • Zhu, M. L., Nagavalli, A. & Su, M. A. Aire deficiency promotes TRP-1-specific immune rejection of melanoma. Most cancers Res. 73, 2104–2116 (2013).

    Article 
    CAS 

    Google Scholar
     

  • Lizotte, P. H. et al. In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic most cancers. Nat. Nanotechnol. 11, 295–303 (2015).

    Article 

    Google Scholar
     

  • Gollob, J. A. et al. Section I trial of twice-weekly intravenous interleukin 12 in sufferers with metastatic renal cell most cancers or malignant melanoma: means to keep up IFN-gamma induction is related to scientific response. Clin. Most cancers Res. 6, 1678–1692 (2000).

    CAS 

    Google Scholar
     

  • Smyth, M. J., Taniguchi, M. & Avenue, S. E. The anti-tumor exercise of IL-12: mechanisms of innate immunity which can be mannequin and dose dependent. J. Immunol. 165, 2665–2670 (2000).

    Article 
    CAS 

    Google Scholar
     

  • Xue, D. et al. A tumor-specific pro-IL-12 prompts preexisting cytotoxic T cells to regulate established tumors. Sci. Immunol. 7, eabi6899 (2022).

    Article 
    CAS 

    Google Scholar
     

  • Karin, N. Chemokines within the panorama of most cancers immunotherapy: how they and their receptors can be utilized to show chilly tumors into scorching ones? Cancers 13, 6317 (2021).

    Article 
    CAS 

    Google Scholar
     

  • Jones, D. S. 2nd et al. Cell surface-tethered IL-12 repolarizes the tumor immune microenvironment to boost the efficacy of adoptive T cell remedy. Sci. Adv. 8, eabi8075 (2022).

    Article 
    CAS 

    Google Scholar
     

  • Rubinstein, M. P. et al. Ex vivo interleukin-12-priming throughout CD8(+) T cell activation dramatically improves adoptive T cell switch antitumor efficacy in a lymphodepleted host. J. Am. Coll. Surg. 214, 700–707 (2012).

    Article 

    Google Scholar
     

  • Müller, J. M. et al. In vivo induction of interferon gamma expression in gray horses with metastatic melanoma ensuing from direct injection of plasmid DNA coding for equine interleukin 12. Schweiz Arch. Tierheilkd. 153, 509–513 (2011).

    Article 

    Google Scholar
     

  • Goldszmid, R. S. et al. NK cell-derived interferon-γ orchestrates mobile dynamics and the differentiation of monocytes into dendritic cells on the web site of an infection. Immunity 36, 1047–1059 (2012).

    Article 
    CAS 

    Google Scholar
     

  • Kerkar, S. P. et al. Collapse of the tumor stroma is triggered by IL-12 induction of Fas. Mol. Ther. 21, 1369–1377 (2013).

    Article 
    CAS 

    Google Scholar
     

  • Geall, A. J. et al. Nonviral supply of self-amplifying RNA vaccines. Proc. Natl Acad. Sci. USA 109, 14604–14609 (2012).

    Article 
    CAS 

    Google Scholar
     

  • [ad_2]

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here